Molecular genetics of Alzheimer's disease: An update

References

• Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991; 82: 239–59
   PubMed Web of Science ®Google Scholar
• Cruts M, Van Broeckhoven C. Molecular genetics of Alzheimer's disease. Ann Med. 1998; 30: 560–5
   PubMed Web of Science ®Google Scholar
• Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000; 54: S4–S9
   PubMed Web of Science ®Google Scholar
• Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006; 63: 168–74
   PubMed Web of Science ®Google Scholar
• Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997; 278: 1349–56
   PubMed Web of Science ®Google Scholar
• Slooter AJ, Cruts M, Kalmijn S, Hofman A, Breteler MM, Van Broeckhoven C, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol. 1998; 55: 964–8
   PubMedGoogle Scholar
• Warwick DE, Payami H, Nemens EJ, Nochlin D, Bird TD, Schellenberg GD, et al. The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet. 2000; 66: 196–204
   Google Scholar
• Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991; 349: 704–6
   PubMed Web of Science ®Google Scholar
• Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 1985; 17: 278–82
   PubMed Web of Science ®Google Scholar
• Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985; 82: 4245–9
   PubMed Web of Science ®Google Scholar
• Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987; 325: 733–6
   PubMed Web of Science ®Google Scholar
• George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins PC, et al. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science. 1987; 235: 885–90
   PubMedGoogle Scholar
• George-Hyslop PH, Haines JL, Farrer LA, Polinsky R, Van Broeckhoven C, Goate A, et al. Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. FAD Collaborative Study Group. Nature. 1990; 347: 194–7
   Google Scholar
• Van Broeckhoven C, Haan J, Bakker E, Hardy JA, Van Hul W, Wehnert A, et al. Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). Science. 1990; 248: 1120–2
   PubMed Web of Science ®Google Scholar
• Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science. 1990; 248: 1124–6
   PubMed Web of Science ®Google Scholar
• Haan J, Hardy JA, Roos RA. Hereditary cerebral hemorrhage with amyloidosis—Dutch type: its importance for Alzheimer research. Trends Neurosci. 1991; 14: 231–4
   PubMedGoogle Scholar
• Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet. 1992; 1: 345–7
   PubMed Web of Science ®Google Scholar
• Hendriks L, van Duijn CM, Cras P, Cruts M, Van Hul W, van Harskamp F, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet. 1992; 1: 218–21
   PubMed Web of Science ®Google Scholar
• van Duijn CM, Hendriks L, Cruts M, Hardy JA, Hofman A, Van Broeckhoven C. Amyloid precursor protein gene mutation in early-onset Alzheimer's disease. Lancet. 1991; 337: 978
   PubMed Web of Science ®Google Scholar
• Yoshikai S, Sasaki H, Doh-ura K, Furuya H, Sakaki Y. Genomic organization of the human amyloid beta-protein precursor gene. Gene. 1990; 87: 257–63
   PubMed Web of Science ®Google Scholar
• Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 1992; 359: 322–5
   PubMed Web of Science ®Google Scholar
• Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science. 1992; 258: 126–9
   PubMed Web of Science ®Google Scholar
• Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science. 1990; 248: 1122–4
   PubMed Web of Science ®Google Scholar
• Estus S, Golde TE, Kunishita T, Blades D, Lowery D, Eisen M, et al. Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor. Science. 1992; 255: 726–8
   PubMed Web of Science ®Google Scholar
• Golde TE, Estus S, Younkin LH, Selkoe DJ, Younkin SG. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science. 1992; 255: 728–30
   PubMed Web of Science ®Google Scholar
• Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature. 1992; 359: 325–7
   PubMed Web of Science ®Google Scholar
• Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999; 286: 735–41
   PubMed Web of Science ®Google Scholar
• De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999; 398: 518–22
   PubMed Web of Science ®Google Scholar
• Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999; 398: 513–7
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 1994; 13: 45–53
   PubMed Web of Science ®Google Scholar
• Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, Condron MM, et al. Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep. 2001; 2: 835–41
   PubMed Web of Science ®Google Scholar
• Gu Y, Misonou H, Sato T, Dohmae N, Takio K, Ihara Y. Distinct intramembrane cleavage of the beta-amyloid precursor protein family resembling gamma-secretase-like cleavage of Notch. J Biol Chem. 2001; 276: 35235–8
   PubMed Web of Science ®Google Scholar
• Zhao G, Mao G, Tan J, Dong Y, Cui MZ, Kim SH, et al. Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein. J Biol Chem. 2004; 279: 50647–50
   PubMedGoogle Scholar
• Zhao G, Cui MZ, Mao G, Dong Y, Tan J, Sun L, et al. gamma-Cleavage is dependent on zeta-cleavage during the proteolytic processing of amyloid precursor protein within its transmembrane domain. J Biol Chem. 2005; 280: 37689–97
   PubMed Web of Science ®Google Scholar
• Kakuda N, Funamoto S, Yagishita S, Takami M, Osawa S, Dohmae N, et al. Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase. J Biol Chem. 2006; 281: 14776–86
   PubMed Web of Science ®Google Scholar
• Funamoto S, Morishima-Kawashima M, Tanimura Y, Hirotani N, Saido TC, Ihara Y. Truncated carboxyl-terminal fragments of beta-amyloid precursor protein are processed to amyloid beta-proteins 40 and 42. Biochemistry. 2004; 43: 13532–40
   PubMed Web of Science ®Google Scholar
• Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, Horikoshi Y, et al. Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J Neurosci. 2005; 25: 436–45
   PubMed Web of Science ®Google Scholar
• Yagishita S, Morishima-Kawashima M, Tanimura Y, Ishiura S, Ihara Y. DAPT-induced intracellular accumulations of longer amyloid beta-proteins: further implications for the mechanism of intramembrane cleavage by gamma-secretase. Biochemistry. 2006; 45: 3952–60
   Google Scholar
• Theuns J, Marjaux E, Vandenbulcke M, Van Laere K, Kumar-Singh S, Bormans G, et al. Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment. Hum Mutat. 2006; 27: 888–96
   Google Scholar
• Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 1992; 360: 672–4
   PubMed Web of Science ®Google Scholar
• Cai XD, Golde TE, Younkin SG. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science. 1993; 259: 514–6
   PubMed Web of Science ®Google Scholar
• Qahwash I, He W, Tomasselli A, Kletzien RF, Yan R. Processing amyloid precursor protein at the beta-site requires proper orientation to be accessed by BACE1. J Biol Chem. 2004; 279: 39010–6
   Google Scholar
• De Jonghe C, Esselens C, Kumar-Singh S, Craessaerts K, Serneels S, Checler F, et al. Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum Mol Genet. 2001; 10: 1665–71
   PubMed Web of Science ®Google Scholar
• Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Jr, Eckman C, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994; 264: 1336–40
   PubMed Web of Science ®Google Scholar
• Tamaoka A, Odaka A, Ishibashi Y, Usami M, Sahara N, Suzuki N, et al. APP717 missense mutation affects the ratio of amyloid beta protein species (A beta 1–42/43 and a beta 1–40) in familial Alzheimer's disease brain. J Biol Chem. 1994; 269: 32721–4
   PubMed Web of Science ®Google Scholar
• Kwok JB, Li QX, Hallupp M, Whyte S, Ames D, Beyreuther K, et al. Novel Leu723Pro amyloid precursor protein mutation increases amyloid beta42(43) peptide levels and induces apoptosis. Ann Neurol. 2000; 47: 249–53
   PubMed Web of Science ®Google Scholar
• Sato T, Dohmae N, Qi Y, Kakuda N, Misonou H, Mitsumori R, et al. Potential link between amyloid beta-protein 42 and C-terminal fragment gamma 49–99 of beta-amyloid precursor protein. J Biol Chem. 2003; 278: 24294–301
   PubMedGoogle Scholar
• Ma QH, Futagawa T, Yang WL, Jiang XD, Zeng L, Takeda Y, et al. A TAG1-APP signalling pathway through Fe65 negatively modulates neurogenesis. Nat Cell Biol. 2008; 10: 283–94
   PubMed Web of Science ®Google Scholar
• Kerr ML, Small DH. Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development. J Neurosci Res. 2005; 80: 151–9
   Google Scholar
• Van Broeckhoven C, Kumar-Singh S. Genetics and pathology of alpha-secretase site AbetaPP mutations in the understanding of Alzheimer's disease. J Alzheimers Dis. 2006; 9: 389–98
   Google Scholar
• Haass C, Hung AY, Selkoe DJ, Teplow DB. Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. J Biol Chem. 1994; 269: 17741–8
   PubMed Web of Science ®Google Scholar
• De Jonghe C, Zehr C, Yager D, Prada CM, Younkin S, Hendriks L, et al. Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiol Dis. 1998; 5: 281–6
   PubMed Web of Science ®Google Scholar
• Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The ‘Arctic’ APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001; 4: 887–93
   PubMed Web of Science ®Google Scholar
• Watson DJ, Selkoe DJ, Teplow DB. Effects of the amyloid precursor protein Glu693→Gln ‘Dutch’ mutation on the production and stability of amyloid beta-protein. Biochem J. 1999; 340 Pt 3: 703–9
   Google Scholar
• Clements A, Walsh DM, Williams CH, Allsop D. Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer's amyloid beta/A4 peptide. Neurosci Lett. 1993; 161: 17–20
   PubMed Web of Science ®Google Scholar
• Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem. 1997; 272: 22364–72
   PubMed Web of Science ®Google Scholar
• Wisniewski T, Ghiso J, Frangione B. Peptides homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation. Biochem Biophys Res Commun. 1991; 179: 1247–54
   PubMed Web of Science ®Google Scholar
• Van Nostrand WE, Melchor JP, Cho HS, Greenberg SM, Rebeck GW. Pathogenic effects of D23N Iowa mutant amyloid beta-protein. J Biol Chem. 2001; 276: 32860–6
   PubMed Web of Science ®Google Scholar
• Kamino K, Orr HT, Payami H, Wijsman EM, Alonso ME, Pulst SM, et al. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am J Hum Genet. 1992; 51: 998–1014
   PubMed Web of Science ®Google Scholar
• Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol. 2001; 49: 697–705
   PubMed Web of Science ®Google Scholar
• Walsh DM, Hartley DM, Condron MM, Selkoe DJ, Teplow DB. In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692→Gly) Alzheimer's disease. Biochem J. 2001; 355: 869–77
   PubMedGoogle Scholar
• Davis J, Van Nostrand WE. Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein. Proc Natl Acad Sci U S A. 1996; 93: 2996–3000
   PubMed Web of Science ®Google Scholar
• Verbeek MM, de Waal RM, Schipper JJ, Van Nostrand WE. Rapid degeneration of cultured human brain pericytes by amyloid beta protein. J Neurochem. 1997; 68: 1135–41
   PubMed Web of Science ®Google Scholar
• Wang Z, Natte R, Berliner JA, van Duinen SG, Vinters HV. Toxicity of Dutch (E22Q) and Flemish (A21G) mutant amyloid beta proteins to human cerebral microvessel and aortic smooth muscle cells. Stroke. 2000; 31: 534–8
   Google Scholar
• Melchor JP, McVoy L, Van Nostrand WE. Charge alterations of E22 enhance the pathogenic properties of the amyloid beta-protein. J Neurochem. 2000; 74: 2209–12
   PubMed Web of Science ®Google Scholar
• Eisenhauer PB, Johnson RJ, Wells JM, Davies TA, Fine RE. Toxicity of various amyloid beta peptide species in cultured human blood-brain barrier endothelial cells: increased toxicity of dutch-type mutant. J Neurosci Res. 2000; 60: 804–10
   PubMed Web of Science ®Google Scholar
• Kumar-Singh S, Julliams A, Nuydens R, Ceuterick C, Labeur C, Serneels S, et al. In vitro studies of Flemish, Dutch, and wild-type beta-amyloid provide evidence for two-staged neurotoxicity. Neurobiol Dis. 2002; 11: 330–40
   Google Scholar
• Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006; 38: 24–6
   PubMed Web of Science ®Google Scholar
• Cabrejo L, Guyant-Marechal L, Laquerriere A, Vercelletto M, De la Fourniere F, Thomas-Anterion C, et al. Phenotype associated with APP duplication in five families. Brain. 2006; 129: 2966–76
   PubMed Web of Science ®Google Scholar
• Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain. 2006; 129: 2977–83
   PubMed Web of Science ®Google Scholar
• Rovelet-Lecrux A, Frebourg T, Tuominen H, Majamaa K, Campion D, Remes AM. APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. J Neurol Neurosurg Psychiatry. 2007; 78: 1158–9
   PubMedGoogle Scholar
• Theuns J, Brouwers N, Engelborghs S, Sleegers K, Bogaerts V, Corsmit E, et al. Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Am J Hum Genet. 2006; 78: 936–46
   PubMed Web of Science ®Google Scholar
• Brouwers N, Sleegers K, Engelborghs S, Bogaerts V, Serneels S, Kamali K, et al. Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer's disease. Brain. 2006; 129: 2984–91
   Google Scholar
• Guyant-Marechal L, Rovelet-Lecrux A, Goumidi L, Cousin E, Hannequin D, Raux G, et al. Variations in the APP gene promoter region and risk of Alzheimer disease. Neurology. 2007; 68: 684–7
   Google Scholar
• Yin YI, Bassit B, Zhu L, Yang X, Wang C, Li YM. Gamma-secretase substrate concentration modulates the abeta 42/abeta 40 ratio: Implications for Alzheimer's disease. J Biol Chem. 2007; 282: 23639–44
   PubMed Web of Science ®Google Scholar
• Tanzi RE, George-Hyslop PH, Haines JL, Polinsky RJ, Nee L, Foncin JF, et al. The genetic defect in familial Alzheimer's disease is not tightly linked to the amyloid beta-protein gene. Nature. 1987; 329: 156–7
   PubMedGoogle Scholar
• Van Broeckhoven C, Genthe AM, Vandenberghe A, Horsthemke B, Backhovens H, Raeymaekers P, et al. Failure of familial Alzheimer's disease to segregate with the A4-amyloid gene in several European families. Nature. 1987; 329: 153–5
   PubMed Web of Science ®Google Scholar
• Crawford F, Hardy J, Mullan M, Goate A, Hughes D, Fidani L, et al. Sequencing of exons 16 and 17 of the beta-amyloid precursor protein gene in 14 families with early onset Alzheimer's disease fails to reveal mutations in the beta-amyloid sequence. Neurosci Lett. 1991; 133: 1–2
   PubMedGoogle Scholar
• Tanzi RE, Vaula G, Romano DM, Mortilla M, Huang TL, Tupler RG, et al. Assessment of amyloid beta-protein precursor gene mutations in a large set of familial and sporadic Alzheimer disease cases. Am J Hum Genet. 1992; 51: 273–82
   Google Scholar
• Schellenberg GD, Anderson L, O'dahl S, Wisjman EM, Sadovnick AD, Ball MJ, et al. APP717, APP693, and PRIP gene mutations are rare in Alzheimer disease. Am J Hum Genet. 1991; 49: 511–7
   PubMed Web of Science ®Google Scholar
• Schellenberg GD, Bird TD, Wijsman EM, Orr HT, Anderson L, Nemens E, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science. 1992; 258: 668–71
   PubMed Web of Science ®Google Scholar
• Van Broeckhoven C, Backhovens H, Cruts M, De Winter G, Bruyland M, Cras P, et al. Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q24.3. Nat Genet. 1992; 2: 335–9
   PubMed Web of Science ®Google Scholar
• George-Hyslop P, Haines J, Rogaev E, Mortilla M, Vaula G, Pericak-Vance M, et al. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nat Genet. 1992; 2: 330–4
   Google Scholar
• Mullan M, Houlden H, Windelspecht M, Fidani L, Lombardi C, Diaz P, et al. A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin gene. Nat Genet. 1992; 2: 340–2
   PubMed Web of Science ®Google Scholar
• Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995; 375: 754–60
   PubMed Web of Science ®Google Scholar
• Cruts M, Backhovens H, Wang SY, Van Gassen G, Theuns J, De Jonghe CD, et al. Molecular genetic analysis of familial early-onset Alzheimer's disease linked to chromosome 14q24.3. Hum Mol Genet. 1995; 4: 2363–71
   PubMedGoogle Scholar
• Clark RF, Hutton M, Fuldner M, Froelich S, Karran E, Talbot C, et al. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Alzheimer's Disease Collaborative Group. Nat Genet. 1995; 11: 219–22
   Google Scholar
• Bird TD, Lampe TH, Nemens EJ, Sumi SM, Nochlin D, Schellenberg GD, et al. Characteristics of familial Alzheimer's disease in nine kindreds of Volga German ancestry. Prog Clin Biol Res. 1989; 317: 229–34
   PubMedGoogle Scholar
• Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, Weber JL, et al. A familial Alzheimer's disease locus on chromosome 1. Science. 1995; 269: 970–3
   PubMed Web of Science ®Google Scholar
• Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995; 269: 973–7
   PubMed Web of Science ®Google Scholar
• Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995; 376: 775–8
   PubMed Web of Science ®Google Scholar
• Cruts M, Van Broeckhoven C. Presenilin mutations in Alzheimer's disease. Hum Mutat. 1998; 11: 183–90
   PubMed Web of Science ®Google Scholar
• Cruts M, van Duijn CM, Backhovens H, Van den BM, Wehnert A, Serneels S, et al. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet. 1998; 7: 43–51
   PubMed Web of Science ®Google Scholar
• Lao JI, Beyer K, Fernandez-Novoa L, Cacabelos R. A novel mutation in the predicted TM2 domain of the presenilin 2 gene in a Spanish patient with late-onset Alzheimer's disease. Neurogenetics. 1998; 1: 293–6
   Google Scholar
• Zekanowski C, Styczynska M, Peplonska B, Gabryelewicz T, Religa D, Ilkowski J, et al. Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer's disease in Poland. Exp Neurol. 2003; 184: 991–6
   PubMed Web of Science ®Google Scholar
• Larner AJ, Ray PS, Doran M. The R269H mutation in presenilin-1 presenting as late-onset autosomal dominant Alzheimer's disease. J Neurol Sci. 2007; 252: 173–6
   Google Scholar
• Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, Fagan AM, et al. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann Neurol. 2007; 61: 446–53
   Google Scholar
• Brouwers N, Sleegers K, Theuns J, Engelborghs S, Bogaerts V, Serneels S, et al. Contribution of dementia genes to Alzheimer's disease in Belgium. Alzheimer. s Dement. 2006; 2(Suppl 1)S191
   Google Scholar
• Rogaev EI, Sherrington R, Wu C, Levesque G, Liang Y, Rogaeva EA, et al. Analysis of the 5′ sequence, genomic structure, and alternative splicing of the presenilin-1 gene (PSEN1) associated with early onset Alzheimer disease. Genomics. 1997; 40: 415–24
   PubMed Web of Science ®Google Scholar
• Levy-Lahad E, Poorkaj P, Wang K, Fu YH, Oshima J, Mulligan J, et al. Genomic structure and expression of STM2, the chromosome 1 familial Alzheimer disease gene. Genomics. 1996; 34: 198–204
   Google Scholar
• Kovacs DM, Fausett HJ, Page KJ, Kim TW, Moir RD, Merriam DE, et al. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med. 1996; 2: 224–9
   PubMed Web of Science ®Google Scholar
• Lee MK, Slunt HH, Martin LJ, Thinakaran G, Kim G, Gandy SE, et al. Expression of presenilin 1 and 2 (PS1 and PS2) in human and murine tissues. J Neurosci. 1996; 16: 7513–25
   PubMedGoogle Scholar
• Suzuki T, Nishiyama K, Murayama S, Yamamoto A, Sato S, Kanazawa I, et al. Regional and cellular presenilin 1 gene expression in human and rat tissues. Biochem Biophys Res Commun. 1996; 219: 708–13
   Google Scholar
• Li X, Greenwald I. Membrane topology of the C. elegans SEL-12 presenilin. Neuron. 1996; 17: 1015–21
   PubMedGoogle Scholar
• Li X, Greenwald I. Additional evidence for an eight-transmembrane-domain topology for Caenorhabditis elegans and human presenilins. Proc Natl Acad Sci U S A. 1998; 95: 7109–14
   PubMed Web of Science ®Google Scholar
• Doan A, Thinakaran G, Borchelt DR, Slunt HH, Ratovitsky T, Podlisny M, et al. Protein topology of presenilin 1. Neuron. 1996; 17: 1023–30
   PubMed Web of Science ®Google Scholar
• Dewji NN, Singer SJ. The seven-transmembrane spanning topography of the Alzheimer disease-related presenilin proteins in the plasma membranes of cultured cells. Proc Natl Acad Sci U S A. 1997; 94: 14025–30
   Google Scholar
• Dewji NN, Valdez D, Singer SJ. The presenilins turned inside out: implications for their structures and functions. Proc Natl Acad Sci U S A. 2004; 101: 1057–62
   PubMedGoogle Scholar
• Laudon H, Hansson EM, Melen K, Bergman A, Farmery MR, Winblad B, et al. A nine-transmembrane domain topology for presenilin 1. J Biol Chem. 2005; 280: 35352–60
   PubMed Web of Science ®Google Scholar
• Spasic D, Tolia A, Dillen K, Baert V, De Strooper B, Vrijens S, et al. Presenilin-1 maintains a nine-transmembrane topology throughout the secretory pathway. J Biol Chem. 2006; 281: 26569–77
   Google Scholar
• Henricson A, Kall L, Sonnhammer EL. A novel transmembrane topology of presenilin based on reconciling experimental and computational evidence. FEBS J. 2005; 272: 2727–33
   Google Scholar
• Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron. 1996; 17: 181–90
   PubMed Web of Science ®Google Scholar
• Mercken M, Takahashi H, Honda T, Sato K, Murayama M, Nakazato Y, et al. Characterization of human presenilin 1 using N-terminal specific monoclonal antibodies: Evidence that Alzheimer mutations affect proteolytic processing. FEBS Lett. 1996; 389: 297–303
   Google Scholar
• Ward RV, Davis JB, Gray CW, Barton AJ, Bresciani LG, Caivano M, et al. Presenilin-1 is processed into two major cleavage products in neuronal cell lines. Neurodegeneration. 1996; 5: 293–8
   Google Scholar
• Podlisny MB, Citron M, Amarante P, Sherrington R, Xia W, Zhang J, et al. Presenilin proteins undergo heterogeneous endoproteolysis between Thr291 and Ala299 and occur as stable N- and C-terminal fragments in normal and Alzheimer brain tissue. Neurobiol Dis. 1997; 3: 325–37
   PubMed Web of Science ®Google Scholar
• Kim TW, Pettingell WH, Hallmark OG, Moir RD, Wasco W, Tanzi RE. Endoproteolytic cleavage and proteasomal degradation of presenilin 2 in transfected cells. J Biol Chem. 1997; 272: 11006–10
   Google Scholar
• Shirotani K, Takahashi K, Ozawa K, Kunishita T, Tabira T. Determination of a cleavage site of presenilin 2 protein in stably transfected SH-SY5Y human neuroblastoma cell lines. Biochem Biophys Res Commun. 1997; 240: 728–31
   Google Scholar
• Steiner H, Capell A, Pesold B, Citron M, Kloetzel PM, Selkoe DJ, et al. Expression of Alzheimer's disease-associated presenilin-1 is controlled by proteolytic degradation and complex formation. J Biol Chem. 1998; 273: 32322–31
   PubMed Web of Science ®Google Scholar
• Saura CA, Tomita T, Davenport F, Harris CL, Iwatsubo T, Thinakaran G. Evidence that intramolecular associations between presenilin domains are obligatory for endoproteolytic processing. J Biol Chem. 1999; 274: 13818–23
   Google Scholar
• Citron M, Eckman CB, Diehl TS, Corcoran C, Ostaszewski BL, Xia W, et al. Additive effects of PS1 and APP mutations on secretion of the 42-residue amyloid beta-protein. Neurobiol Dis. 1998; 5: 107–16
   PubMed Web of Science ®Google Scholar
• Tomita T, Tokuhiro S, Hashimoto T, Aiba K, Saido TC, Maruyama K, et al. Molecular dissection of domains in mutant presenilin 2 that mediate overproduction of amyloidogenic forms of amyloid beta peptides. Inability of truncated forms of PS2 with familial Alzheimer's disease mutation to increase secretion of Abeta42. J Biol Chem. 1998; 273: 21153–60
   Google Scholar
• De Strooper B, Beullens M, Contreras B, Levesque L, Craessaerts K, Cordell B, et al. Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's disease-associated presenilins. J Biol Chem. 1997; 272: 3590–8
   PubMedGoogle Scholar
• Annaert WG, Levesque L, Craessaerts K, Dierinck I, Snellings G, Westaway D, et al. Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons. J Cell Biol. 1999; 147: 277–94
   PubMed Web of Science ®Google Scholar
• Culvenor JG, Maher F, Evin G, Malchiodi-Albedi F, Cappai R, Underwood JR, et al. Alzheimer's disease-associated presenilin 1 in neuronal cells: evidence for localization to the endoplasmic reticulum-Golgi intermediate compartment. J Neurosci Res. 1997; 49: 719–31
   PubMed Web of Science ®Google Scholar
• Levitan D, Greenwald I. Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature. 1995; 377: 351–4
   PubMed Web of Science ®Google Scholar
• Wong PC, Zheng H, Chen H, Becher MW, Sirinathsinghji DJ, Trumbauer ME, et al. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature. 1997; 387: 288–92
   PubMed Web of Science ®Google Scholar
• Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell. 1997; 89: 629–39
   PubMed Web of Science ®Google Scholar
• Weidemann A, Paliga K, Durrwang U, Czech C, Evin G, Masters CL, et al. Formation of stable complexes between two Alzheimer's disease gene products: presenilin-2 and beta-amyloid precursor protein. Nat Med. 1997; 3: 328–32
   PubMed Web of Science ®Google Scholar
• Xia W, Zhang J, Perez R, Koo EH, Selkoe DJ. Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease. Proc Natl Acad Sci U S A. 1997; 94: 8208–13
   PubMed Web of Science ®Google Scholar
• Waragai M, Imafuku I, Takeuchi S, Kanazawa I, Oyama F, Udagawa Y, et al. Presenilin 1 binds to amyloid precursor protein directly. Biochem Biophys Res Commun. 1997; 239: 480–2
   Google Scholar
• De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998; 391: 387–90
   PubMed Web of Science ®Google Scholar
• Ye Y, Lukinova N, Fortini ME. Neurogenic phenotypes and altered Notch processing in Drosophila Presenilin mutants. Nature. 1999; 398: 525–9
   PubMed Web of Science ®Google Scholar
• Struhl G, Greenwald I. Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature. 1999; 398: 522–5
   PubMed Web of Science ®Google Scholar
• Song W, Nadeau P, Yuan M, Yang X, Shen J, Yankner BA. Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. Proc Natl Acad Sci U S A. 1999; 96: 6959–63
   PubMed Web of Science ®Google Scholar
• Steiner H, Duff K, Capell A, Romig H, Grim MG, Lincoln S, et al. A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling. J Biol Chem. 1999; 274: 28669–73
   Google Scholar
• Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature. 2000; 405: 689–94
   PubMed Web of Science ®Google Scholar
• Li YM, Lai MT, Xu M, Huang Q, DiMuzio-Mower J, Sardana MK, et al. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci U S A. 2000; 97: 6138–43
   PubMed Web of Science ®Google Scholar
• Capell A, Grunberg J, Pesold B, Diehlmann A, Citron M, Nixon R, et al. The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex. J Biol Chem. 1998; 273: 3205–11
   PubMed Web of Science ®Google Scholar
• Yu G, Chen F, Levesque G, Nishimura M, Zhang DM, Levesque L, et al. The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin. J Biol Chem. 1998; 273: 16470–5
   PubMed Web of Science ®Google Scholar
• Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature. 2000; 407: 48–54
   PubMed Web of Science ®Google Scholar
• Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, et al. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell. 2002; 3: 85–97
   PubMed Web of Science ®Google Scholar
• Goutte C, Tsunozaki M, Hale VA, Priess JR. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci U S A. 2002; 99: 775–9
   PubMed Web of Science ®Google Scholar
• Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of gamma-secretase activity. Nat Cell Biol. 2003; 5: 486–8
   PubMed Web of Science ®Google Scholar
• Fraering PC, Ye W, Strub JM, Dolios G, LaVoie MJ, Ostaszewski BL, et al. Purification and characterization of the human gamma-secretase complex. Biochemistry. 2004; 43: 9774–89
   PubMed Web of Science ®Google Scholar
• Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A. 2003; 100: 6382–7
   PubMed Web of Science ®Google Scholar
• Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, et al. The role of presenilin cofactors in the gamma-secretase complex. Nature. 2003; 422: 438–41
   PubMed Web of Science ®Google Scholar
• Xia W, Wolfe MS. Intramembrane proteolysis by presenilin and presenilin-like proteases. J Cell Sci. 2003; 116: 2839–44
   PubMed Web of Science ®Google Scholar
• Landman N, Kim TW. Got RIP? Presenilin-dependent intramembrane proteolysis in growth factor receptor signaling. Cytokine Growth Factor Rev. 2004; 15: 337–51
   PubMed Web of Science ®Google Scholar
• Annaert W, De SB. A cell biological perspective on Alzheimer's disease. Annu Rev Cell Dev Biol. 2002; 18: 25–51
   PubMedGoogle Scholar
• Murayama O, Honda T, Mercken M, Murayama M, Yasutake K, Nihonmatsu N, et al. Different effects of Alzheimer-associated mutations of presenilin 1 on its processing. Neurosci Lett. 1997; 229: 61–4
   Google Scholar
• Murayama O, Tomita T, Nihonmatsu N, Murayama M, Sun X, Honda T, et al. Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease. Neurosci Lett. 1999; 265: 61–3
   PubMed Web of Science ®Google Scholar
• Okochi M, Ishii K, Usami M, Sahara N, Kametani F, Tanaka K, et al. Proteolytic processing of presenilin-1 (PS-1) is not associated with Alzheimer's disease with or without PS-1 mutations. FEBS Lett. 1997; 418: 162–6
   PubMedGoogle Scholar
• Steiner H, Romig H, Grim MG, Philipp U, Pesold B, Citron M, et al. The biological and pathological function of the presenilin-1 Deltaexon 9 mutation is independent of its defect to undergo proteolytic processing. J Biol Chem. 1999; 274: 7615–8
   Google Scholar
• Martins RN, Turner BA, Carroll RT, Sweeney D, Kim KS, Wisniewski HM, et al. High levels of amyloid-beta protein from S182 (Glu246) familial Alzheimer's cells. Neuroreport. 1995; 7: 217–20
   Google Scholar
• Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996; 2: 864–70
   PubMed Web of Science ®Google Scholar
• Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, et al. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med. 1996; 2: 1146–50
   PubMed Web of Science ®Google Scholar
• Gomez-Isla T, Wasco W, Pettingell WP, Gurubhagavatula S, Schmidt SD, Jondro PD, et al. A novel presenilin-1 mutation: increased beta-amyloid and neurofibrillary changes. Ann Neurol. 1997; 41: 809–13
   PubMedGoogle Scholar
• Mann DM, Iwatsubo T, Cairns NJ, Lantos PL, Nochlin D, Sumi SM, et al. Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43). Ann Neurol. 1996; 40: 149–56
   PubMedGoogle Scholar
• Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-Tur J, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996; 383: 710–3
   PubMed Web of Science ®Google Scholar
• Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1–40 ratio in vitro and in vivo. Neuron. 1996; 17: 1005–13
   PubMed Web of Science ®Google Scholar
• Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med. 1997; 3: 67–72
   PubMed Web of Science ®Google Scholar
• Tomita T, Maruyama K, Saido TC, Kume H, Shinozaki K, Tokuhiro S, et al. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci U S A. 1997; 94: 2025–30
   PubMed Web of Science ®Google Scholar
• Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J Neurol. 2006; 253: 139–58
   PubMed Web of Science ®Google Scholar
• Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens K, Corsmit E, et al. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat. 2006; 27: 686–95
   PubMed Web of Science ®Google Scholar
• Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, Wiltfang J, et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem. 2006; 96: 732–42
   PubMed Web of Science ®Google Scholar
• Walker ES, Martinez M, Brunkan AL, Goate A. Presenilin 2 familial Alzheimer's disease mutations result in partial loss of function and dramatic changes in Abeta 42/40 ratios. J Neurochem. 2005; 92: 294–301
   Google Scholar
• Qi Y, Morishima-Kawashima M, Sato T, Mitsumori R, Ihara Y. Distinct mechanisms by mutant presenilin 1 and 2 leading to increased intracellular levels of amyloid beta-protein 42 in Chinese hamster ovary cells. Biochemistry. 2003; 42: 1042–52
   Google Scholar
• Mehta ND, Refolo LM, Eckman C, Sanders S, Yager D, Perez-Tur J, et al. Increased Abeta42(43) from cell lines expressing presenilin 1 mutations. Ann Neurol. 1998; 43: 256–8
   PubMedGoogle Scholar
• Brunkan AL, Martinez M, Wang J, Walker ES, Beher D, Shearman MS, et al. Two domains within the first putative transmembrane domain of presenilin 1 differentially influence presenilinase and gamma-secretase activity. J Neurochem. 2005; 94: 1315–28
   Google Scholar
• Chen F, Gu Y, Hasegawa H, Ruan X, Arawaka S, Fraser P, et al. Presenilin 1 mutations activate gamma 42-secretase but reciprocally inhibit epsilon-secretase cleavage of amyloid precursor protein (APP) and S3-cleavage of notch. J Biol Chem. 2002; 277: 36521–6
   PubMedGoogle Scholar
• Wiley JC, Hudson M, Kanning KC, Schecterson LC, Bothwell M. Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment. J Neurochem. 2005; 94: 1189–201
   Google Scholar
• Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, Capell A, et al. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci U S A. 2002; 99: 8025–30
   PubMed Web of Science ®Google Scholar
• Zhang DM, Levitan D, Yu G, Nishimura M, Chen F, Tandon A, et al. Mutation of the conserved N-terminal cysteine (Cys92) of human presenilin 1 causes increased A beta42 secretion in mammalian cells but impaired Notch/lin-12 signalling in C. elegans. Neuroreport. 2000; 11: 3227–30
   Google Scholar
• Steiner H, Revesz T, Neumann M, Romig H, Grim MG, Pesold B, et al. A pathogenic presenilin-1 deletion causes abberrant Abeta 42 production in the absence of congophilic amyloid plaques. J Biol Chem. 2001; 276: 7233–9
   PubMedGoogle Scholar
• De Strooper B. Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007; 8: 141–6
   PubMed Web of Science ®Google Scholar
• Wolfe MS. When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007; 8: 136–40
   PubMed Web of Science ®Google Scholar
• Levitan D, Doyle TG, Brousseau D, Lee MK, Thinakaran G, Slunt HH, et al. Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1996; 93: 14940–4
   Google Scholar
• Davis JA, Naruse S, Chen H, Eckman C, Younkin S, Price DL, et al. An Alzheimer's disease-linked PS1 variant rescues the developmental abnormalities of PS1-deficient embryos. Neuron. 1998; 20: 603–9
   Google Scholar
• Qian S, Jiang P, Guan XM, Singh G, Trumbauer ME, Yu H, et al. Mutant human presenilin 1 protects presenilin 1 null mouse against embryonic lethality and elevates Abeta1-42/43 expression. Neuron. 1998; 20: 611–7
   PubMed Web of Science ®Google Scholar
• Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004; 42: 23–36
   PubMed Web of Science ®Google Scholar
• van Duijn CM, Cruts M, Theuns J, Van Gassen G, Backhovens H, Van den Broeck M, et al. Genetic association of the presenilin-1 regulatory region with early-onset Alzheimer's disease in a population-based sample. Eur J Hum Genet. 1999; 7: 801–6
   Google Scholar
• Lambert JC, Mann DM, Harris JM, Chartier-Harlin MC, Cumming A, Coates J, et al. The (48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased Abeta load in brain. J Med Genet. 2001; 38: 353–5
   PubMed Web of Science ®Google Scholar
• Theuns J, Del Favero J, Dermaut B, van Duijn CM, Backhovens H, Van den Broeck MV, et al. Genetic variability in the regulatory region of presenilin 1 associated with risk for Alzheimer's disease and variable expression. Hum Mol Genet. 2000; 9: 325–31
   Web of Science ®Google Scholar
• Riazanskaia N, Lukiw WJ, Grigorenko A, Korovaitseva G, Dvoryanchikov G, Moliaka Y, et al. Regulatory region variability in the human presenilin-2 (PSEN2) gene: potential contribution to the gene activity and risk for AD. Mol Psychiatry. 2002; 7: 891–8
   PubMed Web of Science ®Google Scholar
• Theuns J, Remacle J, Killick R, Corsmit E, Vennekens K, Huylebroeck D, et al. Alzheimer-associated C allele of the promoter polymorphism (22C > T causes a critical neuron-specific decrease of presenilin 1 expression. Hum Mol Genet. 2003; 12: 869–77
   Google Scholar
• Rademakers R, Cruts M, Sleegers K, Dermaut B, Theuns J, Aulchenko Y, et al. Linkage and association studies identify a novel locus for Alzheimer disease at 7q36 in a Dutch population-based sample. Am J Hum Genet. 2005; 77: 643–52
   Google Scholar
• Jimenez-Escrig A, Gomez-Tortosa E, Baron M, Rabano A, Arcos-Burgos M, Palacios LG, et al. A multigenerational pedigree of late-onset Alzheimer's disease implies new genetic causes. Brain. 2005; 128: 1707–15
   Google Scholar
• Ashley-Koch AE, Shao Y, Rimmler JB, Gaskell PC, Welsh-Bohmer KA, Jackson CE, et al. An autosomal genomic screen for dementia in an extended Amish family. Neurosci Lett. 2005; 379: 199–204
   Google Scholar
• van Duijn CM, Hendriks L, Farrer LA, Backhovens H, Cruts M, Wehnert A, et al. A population-based study of familial Alzheimer disease: linkage to chromosomes 14, 19, and 21. Am J Hum Genet. 1994; 55: 714–27
   Google Scholar
• Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998; 393: 702–5
   PubMed Web of Science ®Google Scholar
• Reed LA, Grabowski TJ, Schmidt ML, Morris JC, Goate A, Solodkin A, et al. Autosomal dominant dementia with widespread neurofibrillary tangles. Ann Neurol. 1997; 42: 564–72
   PubMed Web of Science ®Google Scholar
• van Swieten JC, Stevens M, Rosso SM, Rizzu P, Joosse M, de Koning I, et al. Phenotypic variation in hereditary frontotemporal dementia with tau mutations. Ann Neurol. 1999; 46: 617–26
   PubMed Web of Science ®Google Scholar
• Rademakers R, Dermaut B, Peeters K, Cruts M, Heutink P, Goate A, et al. Tau (MAPT) mutation Arg406Trp presenting clinically with Alzheimer disease does not share a common founder in Western Europe. Hum Mutat. 2003; 22: 409–11
   PubMed Web of Science ®Google Scholar
• Ostojic J, Elfgren C, Passant U, Nilsson K, Gustafson L, Lannfelt L, et al. The tau R406W mutation causes progressive presenile dementia with bitemporal atrophy. Dement Geriatr Cogn Disord. 2004; 17: 298–301
   Google Scholar
• Passant U, Ostojic J, Froelich FS, Gustafson L, Lannfelt L, Larsson EM, et al. Familial presenile dementia with bitemporal atrophy. Dement Geriatr Cogn Disord. 2004; 17: 287–92
   Google Scholar
• Rosso SM, Donker KL, Baks T, Joosse M, de Koning I, Pijnenburg Y, et al. Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain. 2003; 126: 2016–22
   PubMed Web of Science ®Google Scholar
• Momeni P Pittman A Lashley T Vandrovcova J Malzer E Luk C , et al Clinical and pathological features of an Alzheimer's disease patient with the MAPT DeltaK280 mutation. Neurobiol Aging. 2007 Aug 25 (Epub ahead of print).
   Google Scholar
• Dermaut B, Kumar-Singh S, Rademakers R, Theuns J, Cruts M, Van Broeckhoven C. Tau is central in the genetic Alzheimer-frontotemporal dementia spectrum. Trends Genet. 2005; 21: 664–72
   Google Scholar
• Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006; 442: 916–9
   PubMed Web of Science ®Google Scholar
• Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006; 442: 920–4
   PubMed Web of Science ®Google Scholar
• Brouwers N, Nuytemans K, van der Zee J, Gijselinck I, Engelborghs S, Theuns J, et al. Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol. 2007; 64: 1436–46
   PubMedGoogle Scholar
• Rademakers R, Baker M, Gass J, Adamson J, Huey ED, Momeni P, et al. Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C(T (Arg493X) mutation: an international initiative. Lancet Neurol. 2007; 6: 857–68
   PubMed Web of Science ®Google Scholar
• Brouwers N Sleegers K Engelborghs S Maurer-Stroh S Gijselinck I van der Zee J , et al Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology. 2008. In press.
   Google Scholar
• van der Zee J, Le Ber I, Maurer-Stroh S, Engelborghs S, Gijselinck I, Camuzat A, et al. Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. Hum Mutat. 2007; 28: 416
   Google Scholar
• Shankaran SS, Capell A, Hruscha AT, Fellerer K, Neumann M, Schmid B, et al. FTLD-U linked missense mutations in the progranulin gene reduce progranulin production and secretion. J Biol Chem. 2008; 283: 1744–53
   PubMed Web of Science ®Google Scholar
• Pericak-Vance MA, Bebout JL, Gaskell PC, Jr, Yamaoka LH, Hung WY, Alberts MJ, et al. Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. Am J Hum Genet. 1991; 48: 1034–50
   PubMed Web of Science ®Google Scholar
• Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90: 1977–81
   PubMed Web of Science ®Google Scholar
• Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991; 541: 163–6
   PubMed Web of Science ®Google Scholar
• Diedrich JF, Minnigan H, Carp RI, Whitaker JN, Race R, Frey W, et al. Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J Virol. 1991; 65: 4759–68
   PubMed Web of Science ®Google Scholar
• Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993; 43: 1467–72
   PubMed Web of Science ®Google Scholar
• Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261: 921–3
   PubMed Web of Science ®Google Scholar
• van Duijn CM, de Knijff P, Cruts M, Wehnert A, Havekes LM, Hofman A, et al. Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nat Genet. 1994; 7: 74–8
   PubMed Web of Science ®Google Scholar
• Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Jr, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994; 7: 180–4
   PubMed Web of Science ®Google Scholar
• Houlden H, Collinge J, Kennedy A, Newman S, Rossor M, Lannfelt L, et al. Apolipoprotein E genotype and Alzheimer's disease. Alzheimer's Disease Collaborative Group. Lancet. 1993; 342: 737–8
   Google Scholar
• George-Hyslop P, McLachlan DC, Tsuda T, Rogaev E, Karlinsky H, Lippa CF, et al. Alzheimer's disease and possible gene interaction. Science. 1994; 263: 537
   Google Scholar
• Nacmias B, Latorraca S, Piersanti P, Forleo P, Piacentini S, Bracco L, et al. ApoE genotype and familial Alzheimer's disease: a possible influence on age of onset in APP717 Val→Ile mutated families. Neurosci Lett. 1995; 183: 1–3
   Google Scholar
• Sorbi S, Nacmias B, Forleo P, Piacentini S, Latorraca S, Amaducci L. Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease. Ann Neurol. 1995; 38: 124–7
   Google Scholar
• Wijsman EM, Daw EW, Yu X, Steinbart EJ, Nochlin D, Bird TD, et al. APOE and other loci affect age-at-onset in Alzheimer's disease families with PS2 mutation. Am J Med Genet B Neuropsychiatr Genet. 2005; 132: 14–20
   Google Scholar
• Van Broeckhoven C, Backhovens H, Cruts M, Martin JJ, Crook R, Houlden H, et al. APOE genotype does not modulate age of onset in families with chromosome 14 encoded Alzheimer's disease. Neurosci Lett. 1994; 169: 179–80
   PubMedGoogle Scholar
• Pastor P, Roe CM, Villegas A, Bedoya G, Chakraverty S, Garcia G, et al. Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol. 2003; 54: 163–9
   Google Scholar
• Bullido MJ, Artiga MJ, Recuero M, Sastre I, Garcia MA, Aldudo J, et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat Genet. 1998; 18: 69–71
   PubMed Web of Science ®Google Scholar
• Lambert JC, Pasquier F, Cottel D, Frigard B, Amouyel P, Chartier-Harlin MC. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. Hum Mol Genet. 1998; 7: 533–40
   PubMedGoogle Scholar
• Mui S, Briggs M, Chung H, Wallace RB, Gomez-Isla T, Rebeck GW, et al. A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the epsilon 4 allele. Neurology. 1996; 47: 196–201
   PubMedGoogle Scholar
• Artiga MJ, Bullido MJ, Frank A, Sastre I, Recuero M, Garcia MA, et al. Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene. Hum Mol Genet. 1998; 7: 1887–92
   PubMed Web of Science ®Google Scholar
• Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007; 39: 17–23
   PubMed Web of Science ®Google Scholar
• Laws SM, Hone E, Gandy S, Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem. 2003; 84: 1215–36
   PubMed Web of Science ®Google Scholar
• Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90: 8098–102
   PubMed Web of Science ®Google Scholar
• Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90: 9649–53
   PubMed Web of Science ®Google Scholar
• Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron. 1993; 11: 575–80
   PubMed Web of Science ®Google Scholar
• Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997; 17: 263–4
   PubMed Web of Science ®Google Scholar
• Kindy MS, Rader DJ. Reduction in amyloid A amyloid formation in apolipoprotein-E-deficient mice. Am J Pathol. 1998; 152: 1387–95
   PubMed Web of Science ®Google Scholar
• Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 1999; 96: 15233–8
   PubMed Web of Science ®Google Scholar
• Ma J, Yee A, Brewer HB, Jr, Das S, Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994; 372: 92–4
   PubMed Web of Science ®Google Scholar
• Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest. 1994; 94: 860–9
   PubMed Web of Science ®Google Scholar
• Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PT, Jr. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A. 1995; 92: 763–7
   PubMed Web of Science ®Google Scholar
• LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem. 1994; 269: 23403–6
   PubMed Web of Science ®Google Scholar
• Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2000; 97: 2892–7
   PubMed Web of Science ®Google Scholar
• Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest. 1999; 103: R15–R21
   PubMed Web of Science ®Google Scholar
• Sparks DL, Scheff SW, Hunsaker JC III, Liu H, Landers T, Gross DR. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994; 126: 88–94
   PubMed Web of Science ®Google Scholar
• Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000; 7: 321–31
   PubMed Web of Science ®Google Scholar
• Bodovitz S, Klein WL. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem. 1996; 271: 4436–40
   PubMed Web of Science ®Google Scholar
• Howland DS, Trusko SP, Savage MJ, Reaume AG, Lang DM, Hirsch JD, et al. Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J Biol Chem. 1998; 273: 16576–82
   PubMed Web of Science ®Google Scholar
• Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998; 95: 6460–4
   PubMed Web of Science ®Google Scholar
• Bertram L Tanzi RE Alzheimer's disease: one disorder, too many genes? Hum Mol Genet. 2004;13 Spec No 1:R135–R41.
   Google Scholar
• Wragg M, Hutton M, Talbot C. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Alzheimer's Disease Collaborative Group. Lancet. 1996; 347: 509–12
   PubMed Web of Science ®Google Scholar
• Dermaut B, Theuns J, Sleegers K, Hasegawa H, Van den Broeck M, Vennekens K, et al. The gene encoding nicastrin, a major gamma-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample. Am J Hum Genet. 2002; 70: 1568–74
   Google Scholar
• Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007; 39: 168–77
   PubMed Web of Science ®Google Scholar
• Bettens K, Brouwers N, Engelborghs S, De Deyn PP, Van Broeckhoven C. SORL1 is genetically associated with increased risk for late-onset Alzheimer disease in the Belgian population. Hum Mutat. 2008; 29: 769–70
   PubMed Web of Science ®Google Scholar
• Ertekin-Taner N, Allen M, Fadale D, Scanlin L, Younkin L, Petersen RC, et al. Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Abeta42 levels and risk for Alzheimer disease. Hum Mutat. 2004; 23: 334–42
   PubMed Web of Science ®Google Scholar
• Kehoe PG, Russ C, McIlory S, Williams H, Holmans P, Holmes C, et al. Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat Genet. 1999; 21: 71–2
   PubMed Web of Science ®Google Scholar
• Finckh U, van Hadeln K, Muller-Thomsen T, Alberici A, Binetti G, Hock C, et al. Association of late-onset Alzheimer disease with a genotype of PLAU, the gene encoding urokinase-type plasminogen activator on chromosome 10q22.2. Neurogenetics. 2003; 4: 213–7
   Google Scholar
• Sodeyama N, Mizusawa H, Yamada M, Itoh Y, Otomo E, Matsushita M. Lack of association of neprilysin polymorphism with Alzheimer's disease and Alzheimer's disease-type neuropathological changes. J Neurol Neurosurg Psychiatry. 2001; 71: 817–8
   PubMed Web of Science ®Google Scholar
• Dermaut B, Croes EA, Rademakers R, Van den Broeck M, Cruts M, Hofman A, et al. PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease. Ann Neurol. 2003; 53: 409–12
   PubMed Web of Science ®Google Scholar
• Li Y, Nowotny P, Holmans P, Smemo S, Kauwe JS, Hinrichs AL, et al. Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Proc Natl Acad Sci U S A. 2004; 101: 15688–93
   PubMed Web of Science ®Google Scholar
• Kuwano R, Miyashita A, Arai H, Asada T, Imagawa M, Shoji M, et al. Dynamin-binding protein gene on chromosome 10q is associated with late-onset Alzheimer's disease. Hum Mol Genet. 2006; 15: 2170–82
   PubMed Web of Science ®Google Scholar
• Grupe A, Li Y, Rowland C, Nowotny P, Hinrichs AL, Smemo S, et al. A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet. 2006; 78: 78–88
   PubMed Web of Science ®Google Scholar
• Li Y, Grupe A, Rowland C, Nowotny P, Kauwe JS, Smemo S, et al. DAPK1 variants are associated with Alzheimer's disease and allele-specific expression. Hum Mol Genet. 2006; 15: 2560–8
   Google Scholar
• Grupe A, Abraham R, Li Y, Rowland C, Hollingworth P, Morgan A, et al. Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet. 2007; 16: 865–73
   PubMed Web of Science ®Google Scholar
• Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry. 2007; 68: 613–8
   PubMed Web of Science ®Google Scholar
• Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, et al. GAB2 Alleles Modify Alzheimer's Risk in APOE varepsilon4 Carriers. Neuron. 2007; 54: 713–20
   PubMed Web of Science ®Google Scholar
• Liu F, Arias-Vasquez A, Sleegers K, Aulchenko YS, Kayser M, Sanchez-Juan P, et al. A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. Am J Hum Genet. 2007; 81: 17–31
   PubMed Web of Science ®Google Scholar
• Giedraitis V, Hedlund M, Skoglund L, Blom E, Ingvast S, Brundin R, et al. New Alzheimer's disease locus on chromosome 8. J Med Genet. 2006; 43: 931–5
   Google Scholar
• Hahs DW, McCauley JL, Crunk AE, McFarland LL, Gaskell PC, Jiang L, et al. A genome-wide linkage analysis of dementia in the Amish. Am J Med Genet B Neuropsychiatr Genet. 2006; 141: 160–6
   Google Scholar
• Lee JH, Mayeux R, Mayo D, Mo J, Santana V, Williamson J, et al. Fine mapping of 10q and 18q for familial Alzheimer's disease in Caribbean Hispanics. Mol Psychiatry. 2004; 9: 1042–51
   Google Scholar
• Lee JH, Cheng R, Santana V, Williamson J, Lantigua R, Medrano M, et al. Expanded genomewide scan implicates a novel locus at 3q28 among Caribbean hispanics with familial Alzheimer disease. Arch Neurol. 2006; 63: 1591–8
   Google Scholar
• Hiltunen M, Mannermaa A, Thompson D, Easton D, Pirskanen M, Helisalmi S, et al. Genome-wide linkage disequilibrium mapping of late-onset Alzheimer's disease in Finland. Neurology. 2001; 57: 1663–8
   Google Scholar
• Farrer LA, Bowirrat A, Friedland RP, Waraska K, Korczyn AD, Baldwin CT. Identification of multiple loci for Alzheimer disease in a consanguineous Israeli-Arab community. Hum Mol Genet. 2003; 12: 415–22
   PubMed Web of Science ®Google Scholar
• Minster RL, DeKosky ST, Kamboh MI. Lack of association of two chromosome 10q24 SNPs with Alzheimer's disease. Neurosci Lett. 2006; 408: 170–2
   Google Scholar
• Minster RL DeKosky ST Kamboh MI No association of dynamin binding protein (DNMBP) gene SNPs and Alzheimer's disease. Neurobiol Aging. 2007 Apr 16 (Epub ahead of print).
   Google Scholar
• Bertram L, Hsiao M, Lange C, Blacker D, Tanzi RE. Single-nucleotide polymorphism rs498055 on chromosome 10q24 is not associated with Alzheimer disease in two independent family samples. Am J Hum Genet. 2006; 79: 180–3
   Google Scholar
• Liang X, Schnetz-Boutaud N, Bartlett J, Allen MJ, Gwirtsman H, Schmechel DE, et al. No association between SNP rs498055 on chromosome 10 and late-onset Alzheimer disease in multiple datasets. Ann Hum Genet. 2008; 72: 141–4
   Google Scholar
• Bettens K Brouwers N Engelborghs S De Pooter T De Deyn PP Sleegers K , et al. DNMBP is genetically associated with Alzheimer dementia in the Belgian population. Neurobiol Aging. 2008 Mar 21 (Epub ahead of print).
   Google Scholar
• Lin PI, Martin ER, Bronson PG, Browning-Large C, Small GW, Schmechel DE, et al. Exploring the association of glyceraldehyde-3-phosphate dehydrogenase gene and Alzheimer disease. Neurology. 2006; 67: 64–8
   Google Scholar
• Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007; 316: 1491–3
   PubMed Web of Science ®Google Scholar
• Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–78.
   Google Scholar
• Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 2007; 316: 1336–41
   PubMed Web of Science ®Google Scholar
• McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007; 316: 1488–91
   PubMed Web of Science ®Google Scholar
• Li Y, Grupe A, Rowland C, Holmans P, Segurado R, Abraham R, et al. Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease. Hum Mol Genet. 2008; 17: 759–67
   Google Scholar
• Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol. 2008; 65: 45–53
   PubMedGoogle Scholar
• Papassotiropoulos A, Stephan DA, Huentelman MJ, Hoerndli FJ, Craig DW, Pearson JV, et al. Common Kibra alleles are associated with human memory performance. Science. 2006; 314: 475–8
   PubMed Web of Science ®Google Scholar